Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2754558 | Clinical Lymphoma Myeloma and Leukemia | 2011 | 11 Pages |
Abstract
The myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders characterized by cytopenias, dysplastic changes in the hematopoietic precursors, and an increased risk of evolving into acute leukemia. Treatment for patients with MDS ranges from supportive care with blood products and/or growth factors up to allogeneic stem cell transplantation. Over the past decade, several novel therapeutic agents have been approved for clinical use. In this article, the current approach for the management of patients with MDS according to their risk category is described and mainly focuses on approved novel agents.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Ali Al-Ameri, Mohamad Cherry, Guillermo Garcia-Manero, Alfonso Quintás-Cardama,